Rianto Setiabudy Dept. of Pharmacology School of Medicine University of Indonesia Jakarta, 30 April 2015.

Slides:



Advertisements
Similar presentations
Gakava L Roche Products Ltd., Welwyn, UK
Advertisements

The Role of Government in Encouraging a High Standard of Ethics in the Healthcare Sector: Indonesia Experience Prof. Agus Purwadianto Senior Adviser to.
Ethics review and oversight for better governance of health research Amar Jesani Indian Journal of Medical Ethics Centre for Studies in Ethics and Rights.
Implementation of Bridging Study-Taiwans Experience Meir-Chyun Tzou, Ph.D. Senior Officer, and Director of Section III, Bureau of Pharmaceutical Affairs.
Want to SAVE a Few Million Dollars?. Give Us the OPPORTUNITY Do Just That and Well.
Post Research Benefits Mandika Wijeyaratne MS, MD, FRCS Dept. of Surgery, Colombo.
AN OVERVIEW OF HEALTH RESEARCH ETHICS IN INDONESIA By : SURIADI GUNAWAN.
Dr. M. Iwasaki 1 Asian Multinational Clinical Trials - Current Status & Future Direction - Dr.Masaru IWASAKI PR Japan Operations Center Aventis Pharma,
Audit Ebru Mutlu-Omega CRO. General Purpose to help quality (to maintain quality at present) to assure quality (make sure that quality in future is maintained)
SOP Melody Lin, Ph.D. Deputy Director, Office for Human Research Protections Director, International Activities Santiago, Chile August.
GCP compliance for GenISIS  This presentation is intended for clinical staff involved in recruiting patients to the GenISIS (Genetics of Influenza Susceptibility.
CORE COMPETENCIES IN CLINICAL & TRANSLATIONAL RESEARCH: The Child Health Perspective I. Clinical & Translational Research Questions: Extract information.
INSTITUTIONAL PHARMACY PRACTICE STANDARDS
Session 6: Data Integrity and Inspection of e-Clinical Computerized Systems May 15, 2011 | Beijing, China Kim Nitahara Principal Consultant and CEO META.
Strategic Approaches to Outsourcing to Clinical Research Organizations Kate Giovino Director of Clinical Operations.
Good Clinical Practice GCP
Healing Hands Clinical Research Services is a Site Management organization with broad spectrum of activities.
Why companies saying or should say “YES” to India for Studies.
3rd Baltic Conference on Medicines Economic Evaluation, Reimbursement and Rational Use of Pharmaceuticals Pricing and Reimbursement of Pharmaceuticals.
Federal Institute for Drugs and Medical Devices The BfArM is a Federal Institute within the portfolio of the Federal Ministry of Health 1 Quality of Bioequivalence.
Clinical Research Conference 2012 Legal, Ethical, and Social Dimensions of Clinical Research Takis Vidalis, Ph. D., Hellenic National Bioethics Commission.
Eureka Pre-Clinical Investigation Animal toxicology Animal pharmacokinetics/ pharmacodynamics Clinical Investigation Phase I Safety and pharmacology Phase.
Assessment of Interchangeable Multisource Medicines Quality of BE Data Dr. Henrike Potthast Training workshop: Assessment of Interchangeable.
05/09/2015www.ecrin.org1 European Clinical Research Infrastructures Network
Good Clinical Practice (GCP)- An introduction Dr Noor Ibrahim Mohamed Sakian.
Target Institute of Medical Education & Research (TIMER) Provides Clinical Research services to Pharmaceutical, Biotechnology product companies right.
FDA Regulatory review in Minutes: What Product Development Executives Need-to-Know. Specifically, frequent causes of recalls and related areas that investigators.
Stakeholders In Clinical Research Government and Regulatory Bodies Professor Phil Warner.
Diversity in Clinical Trials.  Global Clinical Operations & Therapeutic Areas  Rationale, Significance, Importance of Diversity  U.S. Population Projections.
A S Nanivadekar Introduction to GCP. A S Nanivadekar Outline Definition and scope Definition and scope Purpose of clinical research Purpose of clinical.
Research Ethics Review Malaysian experince Dato Dr. Zaki Morad. Chairperson MREC Dr. Lim TO. Member MREC MOH Malaysia.
INTRODUCTION TO RA.
Fourth Annual Medical Research Summit Concurrent Session 4.05 – Managing CROs and SMOs from a Compliance Perspective Michael SwiatochaAprill 23, 2004.
1 32nd WHO South-East Asia Advisory Committee on Health Research Bangkok, Thailand, October 2011 Review of work carried out by Subcommittee on Vaccines.
Organization of pediatrics in the Netherlands History Organization of pediatric care Quality Pediatric training Financing and income Role of pediatricians.
The competition between innovative and generic pharmaceutical companies intensified in the last decades. The models created by innovative pharmaceutical.
System and experiences in health research ethical review in Vietnam system and experiences in health research ethical review in Vietnam.
Capacity Building in Research Ethics Experiences from Thailand Soraj Hongladarom Department of Philosophy, Chulalongkorn University Bangkok, Thailand.
The Global Health Network Marijke Geldenhuys 19 September 2014 Adhering to the GCP Principles.. what does that even mean?
Global Recognition of the Indian Biotech Sector - The Road Ahead Sept 26,2003 Hyderabad.
The impact on practice, costs and outcomes of New Roles for health professionals in Europe (MUNROS) Antoinette de Bont/ associate professor/ Erasmus University.
Cancer Centers In Clinical Trials Sandrine Marreaud Head of Medical Department.
Human Embryos and Gene-editing Research and regulation in China Prof. Zhihong Xu, Peking University & Chinese Academy of Sciences.
MEDICAL SERVICE ADMINISTRATION VIETNAM MINISTRY OF HEALTH
How to Start An Industry Sponsored Clinical Trial
Career Development Ruotao Wang 2012 – 06. For Happiness Career development is important part of your life! Staff working in the Pharmaceutical Industry.
TCI-NHIP/HEU 10 th Caribbean Conference on National Health Financing Initiatives Turks and Caicos Islands October 28—30, 2015 TCI-NHIP/HEU 10 th Caribbean.
Indian Clinical Trials- The Unaddressed Challenges of Regulatory Amendments Dr. N. Srinivas Principal Malla Reddy Institute of Pharmaceutical Sciences.
Strategic Objective 4 To promote the exchange of experiences and regulatory knowledge between NRAs inside and outside PANDRH“ Lessons learned from international.
Bulgarian National Hepatitis Plan and Compassionate Use Regulations Dr. Stanimir Hasardzhiev Executive Director, ELPA Chairperson, Hepasist REPUBLIC OF.
Korea Food & Drug Administration Deputy director Kwang-Soo Joo Korea FDA Sep. 29, 2000 : Korean Good Clinical Practice & Relative Guidelines How to Manage.
Prepared by: Imon Rahman Lecturer Department of Pharmacy BRAC University.
Establishment of Medical Device GMP Requirements Hsiau-Wen Huang, Ph. D. Senior Researcher Bureau of Pharmaceutical Affairs Department of Health.
The Basque Foundation for Health and Innovation Research Demotek Demonstration Unit of Innovative Technologies in Health An opportunity for.
GCP (GOOD CLINICAL PRACTISE)
Responsibilities of Sponsor, Investigator and Monitor
September 18, 2009 Prepared for DIA GCP QA SIAC teleconference 1 GCP QA for Russia and the Ukraine.
CLINICAL TRIALS.
Recent Evolution of New Drug Review and Approval System in Korea
Responsibilities of Sponsor, Investigator and Monitor
Nordic Cooperation on Ethical Review Procedures Nordforsk – nordic trial alliance MIKA SCHEININ
OUS Data: What does the CE Mark Really Mean?
ICH-GCP Avinash Kondawar M. Pharm Lead CRA
Community Participation in Research
How does teamwork improve value. Dr Nils E
REGULATORY PROBLEMS IN CARING OUT PRE- AND POST- AUTHORISATION CLINICAL TRIALS Dr Penka Decheva GCP Inspector, BDA.
Good Clinical Practice
Pharmacovigilance in clinical trials
Bozeman Health Clinical Research
AGREEMENT FOR TRANSPARENCY The Case of Mexico
Presentation transcript:

Rianto Setiabudy Dept. of Pharmacology School of Medicine University of Indonesia Jakarta, 30 April 2015

Introduction (1)  Indonesia is an archipelago with more than islands  Current population: more than 230 millions With per capita income of US $ in 2014  There are 72 medical schools, 32 of them have been accredited A or B  Currently, about 12 medical schools and special hospitals are actively involved in clinical research activity  Until 2014, there were GPs and specialists in Indonesia (Abidin Z – IDI, 2014)

Introduction (2)  Today the implementation of simultaneous global clinical trials are very important to speed up new drug development  Roughly, 1 day delay of marketing approval causes loss of US $ ,-  The implementation of clinical research in Indonesia and other Asian countries is associated with some potential benefits:  Lower trial cost  “Less strict” regulations  Wide variety of diseases  More availability of research subjects  Many tropical diseases could not be explored in non-tropical countries

Introduction (3) o The question is: How can we be assured that:  the quality of the trial meets the global standards?  are there clear regulations that control the conduct of clinical trials in Indonesia?  are the local regulations compatible with the internationally accepted principles?

Fig. 1

Outlines  Ethics Committee  Local regulations  Inspection and audit  GCP  Our strength and weakness  Major health problems in Indonesia  Issues to be settled

Why do we have to do clinical research? 1. It helps us to solve various health problems in the most efficient way 2. It helps us to reduce cost of health care 3. It helps us to use the most efficacious and safe drugs or methods to improve the our health care 4. It improves the scientific image of our scientists and our nation 5. It opens the door for our scientists to contribute to mankind

Ethics Committee  1982: the first EC was established in Indonesia  2003: the MoH established the National Committee on Ethics of Health Research (KNEPK) with task to improve the capability of ECs in Indonesia  Today there are 55 ECs throughout Indonesia registered in the KNEPK, 8 of them have been recognized by the FERCAP: Litbangkes KemKes, FK Unhas, FKUI, FK UGM, FK Unpad, FK Univ. Udayana, FK Univ Brawijaya

Local regulations related to the GCP and clinical trials (1)  All pre-marketing CTs in Indonesia must meet the GCP standard (SK Kabadan POM, 2001)  All of these trials must obtain ethical and authority approvals prior to their implementation.  The procedure to obtain regulatory authority’s approval are well described (Buku CUKB, 2001)  In Indonesia, trials involving drugs already approved for marketing are not required to apply for approval if they are not intended for claiming new indications

Local regulations related to the GCP and clinical trials (2)  In Indonesia, in addition to evaluating the ethical aspect, the ECs must also evaluate the scientific aspect of clinical trial protocols  Majority of pivotal drug-related CTs will be inspected by the regulatory agency (routine and “for cause”)  All CTs must be registered to MoH  All biological materials are not allowed to be sent to foreign countries, except if the assays required for the trials could not be performed by local labs

Issues requiring attention 1.Contract Research Organization 2.Material Transfer Agreement 3.Accreditation of ECs 4.GCP trainings 5.Local insurance companies

Our strengths Availability of :  Hospitals and health centers (puskesmas)  Capable and qualified manpower  Regulations related to clinical research  CROs  Accredited clinical labs  Strong and high quality pharmaceutical industry  Wide variety of diseases

Our weaknesses  Less standardized Ethics Committees  Lack of network in drug development research  Low quality of some clinical trials  Some “less friendly” regulations  Lack of insurance companies  Small number of research-oriented local pharmaceutical industry  Most of our pharmaceutical companies lack spirit to innovate

Our opportunities  The global need to develop new drugs in short period of time  Large patient populations  Competitiveness of research cost  The piling up of health problems in Indonesia

Our threats  Competing countries (especially China, Thailand, and Vietnam)

What do we have to do?  Quality improvement of CT implementation: CRO, inspection, audit, GCP, protection of human subjects  Quality improvement of ECs: accreditation, SOPs, independency, GCP, trainings  Regulations: removal of regulations that may hamper development of the role Indonesian scientists in global clinical research, esp. for premarketing trials

Major communicable diseases in Indonesia Diseases Upper resp. tract infection Pneumonia Lung tuberculosis Hepatitis Diarrhea Malaria (Riskesdas, Ministry of Health of Indonesia, 2013) Table 1

Major non-communicable diseases in Indonesia Diseases Asthma Chronic obstruct. Pulmonary disease Cancer Diabetes mellitus Hiperthyroidism Hypertension Coronary heart disesase Stroke Chronic renal failure Kidney stone Rheumatic diseases (Riskesdas, Ministry of Health of Indonesia, 2013) Table 3

Conclusions  Clinical research is the key solution for various health problems throughout the world  Indonesia potentially has a big opportunity to become a prominent player in clinical research  Some research institutions in Indonesia are ready to carry out high quality clinical research  More opportunity has to be given by the sponsors to Indonesia to show its ability in executing high quality clinical research THANK YOU